An exploratory analysis found different cellular pathway signals in depression and ALS
Original source
Cellular Logistics and Synaptic Vesicle Vulnerability in Major Depressive Disorder and Amyotrophic Lateral Sclerosis Comorbidity: Insights From Nicotinamide Mononucleotide Rescue and Transcriptome-Wide Association Study Integration. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse
Population inferred from the title and abstract by Compass.
An exploratory transcriptome-wide analysis found the strongest pathway signal for major depressive disorder in synaptic vesicle biology. In amyotrophic lateral sclerosis (ALS), no nominated pathway showed significant overall enrichment, although individual genes linked to autophagy, endosomal function and vesicle processes produced candidate signals. The study did not test treatment effects or establish that nicotinamide mononucleotide (NMN) or NAD+ repletion benefits either condition.
Why this matters
The findings may help researchers develop hypotheses about cellular processes shared by depression and ALS, while suggesting that the genetic signals may differ between the conditions. This is early, exploratory work and does not change treatment for people with ALS or depression.
Limitations and context
This was an exploratory secondary analysis of precomputed transcriptome-wide association study results, not a clinical trial or a test of NMN treatment. The strongest depression pathway signal did not survive the study's competitive permutation or Wilcoxon tests, and ALS had no significant overall enrichment among the 10 nominated pathways. The authors state that the findings are not evidence of causal mediation and require future preclinical and clinical study.